Significant differences have not been observed between clinical outcomes according to density in tumor-infiltrating T lymphocytes (TILs) of CD4+/CD8+ lymphocytes, FOXP3+ regulatory T-cells (Tregs), peritumoral and stromal myeloid cells, and PD1-positive and PD-L1-positive immune cells. This evidence concerns the gene CD274 and neoplasm.